Cytomedix acquires stem cell company Aldagen

02/8/2012 | MedCityNews.com

Cytomedix purchased Aldagen for $16 million in stock, expanding the former's pipeline of regenerative therapies. The acquisition "provides Cytomedix with a novel, patent-protected cell selection technology that fits well with our existing commercial products and strengthens our long-range growth profile," Cytomedix CEO Martin Rosendale said.

View Full Article in:

MedCityNews.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT